{"id":"NCT01177722","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants","officialTitle":"Lot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Latin American Infants Concomitantly With Prevenar™ and Rotarix™","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2011-10","completion":"2011-12","firstPosted":"2010-08-09","resultsPosted":"2014-05-05","lastUpdate":"2014-05-05"},"enrollment":1375,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Whooping Cough","Hepatitis B","Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP-T Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP-T Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP-T Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-Hep B-IPV vaccine","otherNames":["Infanrix hexa™"]}],"arms":[{"label":"Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)","type":"EXPERIMENTAL"},{"label":"Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)","type":"EXPERIMENTAL"},{"label":"Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)","type":"EXPERIMENTAL"},{"label":"Group 4: Active Control","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to generate immunogenicity and safety data of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine compared to a control vaccine, Infanrix hexa™ when given along with Prevenar™ and Rotarix™ vaccines.\n\nPrimary Objectives:\n\n* To demonstrate the equivalence of immunogenicity of 3 lots of DTaP-IPV-Hep B-PRP-T vaccine 1 month after a 3-dose primary series (2, 4 and 6 months) when given with Prevenar™ and Rotarix™, in terms of immunoresponses.\n* To demonstrate the non-inferiority of the hexavalent DTaP-IPV-Hep B-PRP-T vaccine to the licensed hexavalent Infanrix hexa vaccine when given with Prevenar™ and Rotarix™.\n\nSecondary Objectives:\n\n* To describe in each group the immunogenicity parameters for all antigens for each vaccine\n* To assess the safety profile in terms of solicited and unsolicited adverse events and serious adverse events in each group for each vaccine.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™","timeFrame":"Day 0 (pre-vaccination) Dose 1 and 30 days post-vaccination","effectByArm":[{"arm":"DTap-IPV-Hep B-PRP~T Batch A","deltaMin":4.02,"sd":null},{"arm":"DTaP-IPV-Hep B-PRP~T Batch B","deltaMin":4.07,"sd":null},{"arm":"DTaP-IPV-Hep B-PRP~T Batch C","deltaMin":4.93,"sd":null},{"arm":"Infanrix Hexa","deltaMin":4.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"55 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":2,"countries":["Colombia","Costa Rica"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":345},"commonTop":["Irritability","Injection Site Pain","Crying","Somnolence","Nasopharyngitis"]}}